<DOC>
	<DOC>NCT02163902</DOC>
	<brief_summary>To investigate the long-term safety and maintenance of efficacy of ATX-101 in reduction of submental fat.</brief_summary>
	<brief_title>Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101</brief_title>
	<detailed_description>No study medication is administered in this study.</detailed_description>
	<criteria>1. Any subject who completed followup visits at 12 and 24 weeks after the last dose in one of the two predecessor studies 2. Willingness to comply with the schedule and procedures of this study. 3. Signed informed consent form (ICF). 1. Subjects who have had any treatment or condition (e.g., pregnancy or metabolic disease, which may lead to unstable weight) that may affect assessment of safety or efficacy since enrollment in the predecessor study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>